Related Experiment Video
Updated: Jul 11, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated
Parisa Bakhshi1, Maryam Nourizadeh2, Laleh Sharifi3
1Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences (IUMS), Hemmat Highway, Tehran, Iran.
Background:
Prostate cancer (PCa) is the second leading cause of cancer-related deaths among men worldwide. Immunotherapy is an emerging treatment modality for cancers that harnesses the immune system's ability to eliminate tumor cells. In particular, dendritic cell (DC) vaccines, have demonstrated promise in eliciting a tumor-specific immune response. In this study, we investigated the potential of using DCs loaded with the MAGE-A2 long peptide to activate T cell cytotoxicity toward PCa cell lines.
Methods:
Here, we generated DCs from monocytes and thoroughly characterized their phenotypic and functional properties. Then, DCs were pulsed with MAGE-A2 long peptide (LP) as an antigen source, and monitored for their transition from immature to mature DCs by assessing the expression levels of several costimulatory and maturation molecules like CD14, HLA-DR, CD40, CD11c, CD80, CD83, CD86, and CCR7. Furthermore, the ability of MAGE-A2 -LP pulsed DCs to stimulate T cell proliferation in a mixed lymphocyte reaction (MLR) setting and induction of cytotoxic T cells (CTLs) in coculture with autologous T cells were examined. Finally, CTLs were evaluated for their capacity to produce interferon-gamma (IFN-γ) and kill PCa cell lines (PC3 and LNCaP).
Results:
The results demonstrated that the antigen-pulsed DCs exhibited a strong ability to stimulate the expansion of T cells. Moreover, the induced CTLs displayed substantial cytotoxicity against the target cells and exhibited increased IFN-γ production during activation compared to the controls.
Conclusions:
Overall, this innovative approach proved efficacious in targeting PCa cell lines, showcasing its potential as a foundation for the development and improved PCa cancer immunotherapy.
Insights
Dendritic cell (DC) vaccines loaded with MAGE-A2 long peptide effectively stimulated T cells, leading to cytotoxic T lymphocytes (CTLs) that killed prostate cancer cells. This immunotherapy approach shows promise for future prostate cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Prostate cancer (PCa) is a significant global health concern, necessitating novel therapeutic strategies.
- Immunotherapy, particularly dendritic cell (DC) vaccines, offers a promising avenue for harnessing the immune system against cancer.
- This study explores DCs pulsed with MAGE-A2 long peptide for T cell activation against PCa.
Purpose of the Study:
- To investigate the efficacy of MAGE-A2 long peptide-pulsed DCs in activating T cell-mediated cytotoxicity against prostate cancer cell lines.
- To characterize the phenotypic and functional maturation of DCs after antigen pulsing.
- To evaluate the induction of antigen-specific cytotoxic T lymphocytes (CTLs) and their anti-tumor activity.
Main Methods:
- Dendritic cells (DCs) were generated from monocytes and characterized for maturation markers (CD14, HLA-DR, CD40, CD11c, CD80, CD83, CD86, CCR7).
- DCs were pulsed with MAGE-A2 long peptide (LP) and co-cultured with autologous T cells to induce CTLs.
- T cell proliferation was assessed via mixed lymphocyte reaction (MLR), and CTL-mediated cytotoxicity and interferon-gamma (IFN-γ) production against PCa cell lines (PC3, LNCaP) were measured.
Main Results:
- Antigen-pulsed DCs effectively stimulated T cell expansion.
- Induced CTLs demonstrated significant cytotoxicity against MAGE-A2-expressing PCa cell lines.
- Elevated IFN-γ production was observed in activated CTLs compared to controls.
Conclusions:
- MAGE-A2 long peptide-pulsed DC immunotherapy is effective in targeting prostate cancer cells.
- This approach shows potential for developing improved immunotherapies for prostate cancer.
- The study highlights the capacity of engineered DCs to elicit a potent anti-tumor immune response.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy